Table 1 Characteristics of studies included in this meta-analysis

From: Association of BRCA2 N372H polymorphism with cancer susceptibility: A comprehensive review and meta-analysis

First author	Year	Cancer type	Race	Source of control	Case	Control	Method	MAF	HWE
Healey	2000	breast	Caucasian	PB	234	266	TaqMan	/	/
Healey	2000	breast	Caucasian	PB	449	453	TaqMan	/	/
Healey	2000	breast	Caucasian	PB	659	866	TaqMan	/	/
Spurdle	2002	breast	Caucasian	PB	1397	775	Taqman	0.26	0.49
Ishitobi	2003	breast	Asian	HB	149	154	PCR-SSCP	0.20	0.10
Menzel	2004	breast	Caucasian	PB	94	152	Pyrosequencingt	0.26	0.76
Menzel	2004	breast	Caucasian	PB	211	912	Pyrosequencingt	0.27	0.90
Freedman	2004	breast	Mixed	PB	1715	2602	Unknown	/	/
Cox	2005	breast	Caucasian	Nested	1285	1660	Taqman	0.27	0.48
Millikan	2005	breast	African	PB	849	675	Taqman	0.13	0.89
Millikan	2005	breast	Caucasian	PB	1265	1135	Taqman	0.28	0.70
Jenkins	2005	breast	Caucasian	Family	1400	800	Unknown	/	/
HBBCS	2006	breast	Caucasian	HB	274	273	Restriction enzyme-based assays	0.32	0.27
HBCS	2006	breast	Caucasian	HB	807	697	Taqman	0.22	0.40
Sheffield	2006	breast	Caucasian	HB	973	956	Taqman	0.30	0.57
LSHTM	2006	breast	Caucasian	Nested	585	598	Restriction enzyme-based assays	0.29	0.28
Madrid	2006	breast	Caucasian	HB	712	767	Taqman and Illumina	0.30	0.39
USRTS	2006	breast	Caucasian	Nested	707	1046	Taqman	0.30	0.34
SEARCH	2006	breast	Caucasian	PB	4454	4537	Taqman	0.28	0.07
KBCP	2006	breast	Caucasian	HB	446	452	Taqman	0.22	0.61
GESBC	2006	breast	Caucasian	PB	602	851	Various	0.29	0.12
Garcia-Closas	2006	breast	Caucasian	PB	3161	2701	Taqman	0.28	0.09
Garcia-Closas	2006	breast	Caucasian	PB	1968	2276	Taqman	0.26	0.18
Johnson	2007	breast	Caucasian	NA	473	2461	Illumina Sentrix Bead Arrays	0.28	0.88
Seymour	2008	breast	Caucasian	HB	263	60	PCR	0.23	0.13
Hu R	2008	breast	Asian	NA	71	85	PCR	0.22	0.16
Dombernowsky	2009	breast	Caucasian	PB	1200	4119	TaqMan	0.28	0.49
Sun	2009	breast	Asian	PB	512	541	PCR	/	/
Li	2011	breast	Asian	HB	152	165	PCR	0.26	0.56
Silva	2011	breast	Mixed	NA	54	20	PCR	/	/
Auranen	2003	Ovarian	Caucasian	PB	680	1546	TaqMan	0.27	0.12
Wenham	2003	Ovarian	Caucasian	PB	312	398	Taqman	0.25	0.81
Beesley	2007	Ovarian	Caucasian	PB	492	948	MALDI-TOF mass spectrophotometric	0.27	0.38
Beesley	2007	Ovarian	Caucasian	PB	930	825	MALDI-TOF mass spectrophotometric	0.26	0.04
Hill	2006	NHL	Mixed	PB	1116	926	Illumina	0.26	0.67
Shen	2006	NHL	Mixed	PB	476	555	Taqman	0.26	0.46
Scott	2007	NHL	Caucasian	PB	676	757	TaqMan	0.29	0.85
Shen	2007	NHL	Caucasian	PB	556	498	TaqMan	0.30	0.46
Salagovic	2012	NHL	Caucasian	HB	107	127	PCR	0.20	0.97
Rudd	2006	CLL	Caucasian	HB	962	2695	Illumina	/	/
Hu	2003	ESCC	Asian	PB	120	231	PCR–SSCP	0.25	0.13
Wu	2006	bladder	Caucasian	PB	604	595	Taqman	0.25	0.76
Debniak	2008	melanoma	Caucasian	PB + HB	627	3819	RTPCR	/	/
Agalliu	2010	prostate	Caucasian	PB	1269	1243	SNPlex™	0.27	0.62
Agalliu	2010	prostate	African	PB	142	79	SNPlex™	0.14	0.66
Kotnis	2012	overall	Asian	HB	109	186	PCR	0.38	0.01

HB, hospital-based; PB, population-based; MAF, minor allele frequency, HWE, Hardy–Weinberg equilibrium; CLL, chronic lymphocytic leukemia; ESCC, esophageal squamous cell carcinoma.

Back to article page

Table 1 Characteristics of studies included in this meta-analysis

Search

Quick links